Del Mar, CA, | May 30, 2023 – American Diversified Holdings Corporation (OTC: ADHC) is announced today announce that the company is in the final stages of developing a state-of-the-art e-commerce site offering CBD products under ADHC brand UNIVERSAL WELLNESS.

ADHC and its operating division UNIVERSAL WELLNESS previously announced a comprehensive alliance with GGII’s leading group of a companies in the CBD and Hemp sector. ADHC’s agreement with Green Globe Intl Group (OTC: GGII), Hempaco (NASDAQ: HPCO) and GGII’s operating subsidiary Green Star Labs provides for a broad range of services and interrelated business activity.

The GGII/HEMPACCO/GREENSTAR group has entered into this alliance with ADHC and will collaborate as outlined below:

• Formulation, manufacturing, private label, inventory management, packaging and shipment logistics with be provided by Green Star Labs under the Universal Wellness and Rolls Choice Brand.
• Jointly design a line of CDB, Dietary Supplements and Cosmetic products to be offered through ADHC’ e-commerce beta platform .
• Introduce and negotiate endorsement agreements with social media influencers and noted HipHop/Rap luminaries. Hempacco currently has relationships deals with Snoop Dogg Brands, rap artist Rick Ross, Hemp Hop Smokables and Cheech and Chong, Hemp Cigarettes.
• Parties have agreed to a financial partnership including share issuances, line of credit for product inventory, capital formation and addition of future management.
• Parties have agreed to assess the develop of ADHC existing brand and future products under development, including products sold under the Rolls Choice Brand of cannabis adhesive pens and Universal Wellness lifestyle and CBD products.

This alliance and new ECommerce business is set to springboard ADHC’S branded products into the rapidly growing CDB market sector. A recent report by Market Research Future (MRFR) indicated the CDB market is expected to reach over $59 billion by 2030 an 18% CAGR.

See: Cannabidiol (CBD) Market Size Worth USD 59.3 Billion

“The GGII/HPCO team is a great alliance partner for ADHC, we can now focus on pushing our brands to the forefront of the CBD and Cannabis markets with a manufacturing and brand building partner that is a dream come true for our shareholder,” commented ADHC management.

About Hempacco (NASDAQ: HPCO)

Hempacco Co., Inc.’s goal is Disrupting Tobacco’s nearly $1 trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing herb, spice, and cannabinoid smokables and rolling paper. Hempacco owns The Real Stuff functional hemp cigarette and rolling paper brand.

Hempacco’s operating segments include:

• • Manufacturing of smokables, hemp rolling paper, and cannabinoid sticks
  • Smokable technology development
  • The Real Stuff brand of functional smokables and rolling paper
  • Cheech and Chong Hemp Cigarettes and Hemp Hop Smokables with Rick Ross
  • Snoop Dogg Joint Venture of Hemp-Derived Products

Learn more at www.hempacco.com.

Order products at www.realstuffsmokables.com.

About Green Globe International, Inc. (OTC: GGII):

Green Globe International is a Fast-Moving Consumer Goods incubator and holding company of intellectual property, products, and companies that better people’s lives by helping them feel and look better inside and out.

Green Globe International (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., (NASDAQ: HPCO) Disrupting Tobacco’s $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. a vending and advertising company, Hempacco Paper Company, Inc., producing The Real Stuff Hemp Smokables and hemp paper smoking products like blunts, tubes, and cones, Cali Vibes, Inc. manufacturing cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivering cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners, StickIt USA, Inc., manufacturing a line of cannabinoid sticks, and HPDG, LLC a partnership with Snoop Dogg to develop hemp-derived consumer goods products.

Green Globe International is publicly traded under the ticker symbol (OTC: GGII). It continues to look for best-in-class companies, products, and patents to create Fast Moving Consumer Goods and channels to sell them, including retail automation and advertising platforms.

ABOUT ADHC/UNIVERSAL WELLNESS

ADHC is a publicly traded holding company trading under the ticker symbol (OTC: ADHC).

ADHC is currently developing two web-based branded businesses.

• Universal Wellness (UWS) is a wellness and lifestyle e-commerce site focused on providing innovative products, news, and the latest healthcare developments

Shares Outstanding: 866 million

Shares Restricted: 301 million

Shares in the Float: 504 million

Investor Contact:

Andrew Birnbaum

Chairman/CEO

CEO@ADHCINVESTOR.com

TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC.

Information contained herein includes forward-looking statements.

SAFE HARBOR

These statements relate to future events or future financial performance, involving known and unknown risks and uncertainties that may cause our actual results to be materially different to performance or achievements expressed. You should not place undue reliance on these statements, since they involve known and unknown risks. Any forward-looking statements reflect the current view with respect to future events and subject to uncertainties.

Contact Details

Andrew Birnbaum, Chairman/CEO

CEO@ADHCINVESTOR.com

West Palm Beach, Florida–(Newsfile Corp. – January 18, 2023) – Nass Valley Gardens Inc., a Nevada registered C-Corp and a wholly owned subsidiary of Nass Valley Gateway Ltd., (CSE: NVG) (OTC Pink: NSVGF) (FSE: 3NVN), announced today that it signed a definite agreement on 12/31/2022 to purchase 100% of Super Scientific Laboratories LLC, a leading manufacturer of products focused on CBD, cannabidiols, vapes, gummies, soaps, lotions and other consumer products.

Nass Valley Gateway Ltd. CEO Michael Semler stated, “We welcome Hershey Jakob and his team at Super Scientific Labs. We have been discussing an acquisition for over a year and are truly excited as our two companies will be stronger together as one, versus standing apart. We will be able to leverage our synergies to drive more creative product development, share greater distribution channels, and be able to compete for larger manufacturing contracts. Their proven manufacturing capabilities are a perfect fit and their growing client base will be accretive to Nass Valley Gardens’ 2023 earnings.”

Audited financials will be available when completed on Nass Valley Gardens Inc’s website. There was no finder’s fee involved in the acquisition.

ABOUT NASS VALLEY GARDENS INC.

Nass Valley Gardens Inc. is a subsidiary of Nass Valley Gateway LTD (NVG), a publicly traded company on the CSE. In 2019, Nass Valley Gateway Ltd began focusing on the sales and distribution of organic, non-GMO hemp-based, CBD products and purchased Nass Valley Gardens Inc and its lineup of CBD products sold via digital sales channels. Nass Valley Gardens’ products target the pain remediation, sleep, focus, dermatology, anti-aging, pet, hair, and beauty markets.

We seek Safe Harbor.

This press release is for information purposes only and does not constitute an offer or sale of the securities mentioned above. Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to Regulation A of the Securities Act of 1933.

Company:

Nass Valley Gardens Inc.
400 Clematis St., Ste 207
West Palm Beach, FL 33418

A subsidiary of:

Nass Valley Gateway Ltd.
422 Richards Street, Suite 170
V6B 2Z4 Vancouver
Canada
Phone: 609-651-0032
E-mail: [email protected]
Internet: www.nassvalleygateway.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

San Diego, California, July 20, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer (“CMO”) of its Phase 1 clinical trial material that a now-resolved cyber-attack on the CMO’s computer systems as well as a planned annual maintenance shutdown will result in a delay in completing production of Skye’s Phase 1 drug to the beginning of September. Skye now expects to initiate enrollment of its Phase 1 clinical study in Q4 2022, report preliminary topline data in early Q1 2023, and report final data in Q2 2023.

Skye’s SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) had most recently been scheduled for production and fill in the first week of July. While the CMO has sufficiently recovered from the recent cyber-attack, planned annual facility maintenance could not be rescheduled. The maintenance schedule has been accelerated and will be conducted through August 30.  Skye’s SBI-100 product is now planned to be produced and filled in the first week of September, with required drug quality testing completed by the first half of October.

“The unpredictable events that have detrimentally affected our production schedule have been frustrating, but we are confident in the renewed commitment of our contract manufacturer to produce our clinical trial material and the schedule to start our planned study,” said Punit Dhillon, CEO and Chair of Skye. “Securing approval for the Australian Human Research Ethics Committee at the end of June was a vital factor to move our Phase 1 forward. While the delay in the Phase 1 is not a welcomed outcome, we are pleased that we continue to progress on the logistics that move us toward enrollment and dosing of the first cohort of patients.

“As we previously noted, we are in parallel progressing our Phase 2 clinical development plan. In our preliminary meeting last winter with the FDA to discuss our planned Investigational New Drug (“IND”) application, the FDA confirmed that, as is standard practice with all ophthalmology clinical studies, it would accept from Skye nonclinical toxicology data for review and approval of its IND and Phase 2 protocol rather than requiring Phase 1 safety data. The Phase 1 study outcome will provide us the benefit of safety and tolerability data of SBI-100 OE but is not a gating factor to initiate Phase 2. We continue to look forward to obtaining Phase 1 data but concurrently developing our clinical plans with the expectation that we can report Phase 2 by year-end 2023.”

About SBI-100 Ophthalmic Emulsion
Increased intraocular pressure (IOP) is a key risk factor in the progression of glaucoma. The first observations that consuming cannabis lowered IOP in humans took place in the early 1970s, which led to a significant amount of research on the effects of cannabinoids in the eye. Independent studies demonstrated that activation of the cannabinoid receptor-type 1 (CB1R) in ocular tissue mediates IOP-lowering. However, no cannabinoid-related drug has been approved for clinical use in the eye due primarily to the shortcomings of current delivery methods of CB1R agonists to the eye in a therapeutically beneficial dose. When cannabinoids are administered systemically, they can lower IOP but also result in undesirable psychotropic effects. Alternatively, extracted natural cannabinoids delivered topically as an eye drop do not penetrate ocular tissue well enough to effectively lower IOP due to the lipophilic, or oily, properties of natural cannabinoids and the aqueous, or watery, surface of the eye.

To address these challenges, Skye developed SBI-100 OE, a proprietary, synthetic cannabinoid derivative possessing a novel molecular structure and formulation that was rationally designed to enable better penetration of ocular tissue and effective topical delivery of a CB1R agonist. In preclinical studies involving three different species, a nanoemulsion formulation of the drug applied topically to the eye resulted in enhanced therapeutic efficacy and duration of response in lowering IOP. Importantly, these studies also demonstrated advantages compared to today’s standard of care and, if clinically validated in subsequent efficacy studies, may provide a suitable therapeutic window to be a new class of medicine for glaucoma.

About Skye Bioscience
Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. The Company’s lead program, SBI-100 OE, is focused on developing a treatment for glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.

CONTACT
Investor Relations
Email: [email protected]
Phone: (858) 410-0266

FORWARD LOOKING STATEMENTS
This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Does CBD have a place in modern dentistry? While this may seem like an odd question, there may be a legitimate case for “CBD toothpaste.” Indeed, there are already a few dentists who’ve begun studying CBD’s effects on teeth and gum health. We’ve even heard from a few patients who enjoy adding a few drops of Tribe CBD oil to their dental hygiene routine.  

So, what’s the deal? Could CBD oil truly brighten your smile; or, is this all just an over-hyped gimmick? While we don’t have all the answers on using CBD for teeth, there are a few fascinating reports on this topic. 

Why Would People Put CBD On Their Teeth? 

The primary reason people are excited about CBD’s potential for dental health is its anti-inflammatory properties. As we’ve mentioned in previous blog posts, many studies suggest topical CBD may reduce joint swelling and pain. Some scientists believe applying CBD to the gums may have similar healing benefits.

Interestingly, one study out of Brazil examined CBD’s effectiveness on inflammatory gum diseases. Although this trial only studied the effects of CBD injections in rats, it suggests CBD’s anti-inflammatory properties could positively influence gum health. 

There are also a few studies that suggest CBD may have antimicrobial compounds. In fact, a few reporters claim CBD may play a role in destroying antibiotic-resistant bacteria. This strong antibacterial potential could play a positive role in oral hygiene. 

How Do You Take Tribe CBD Oil For Dental Health? 

There’s no fancy technique for adding CBD oil to your dental care routine. If you’re curious about using CBD oil on your teeth, place a few drops of CBD oil on top of your toothpaste and brush for at least two minutes. 

If you’re a fan of oil pulling, then you could also add ½ dropperful of Tribe CBD oil to about one tablespoon of coconut oil. You could even experiment with mixing some CBD oil into a wheatgrass shot and swishing for about five minutes. Interestingly, many people believe the chlorophyll in wheatgrass has gum-healing properties.

Of course, the scientific literature on all of these alternative healing methods is still in the preliminary stages. None of these adjunct therapies are intended to treat or heal any dental conditions, nor are they a replacement for regular brushing and flossing. Please only add these therapies to your wellness routine with a dentist’s approval. 

Get Dental Anxiety? Tribe CBD Can Help With That!

Even if you’re not interested in mixing CBD oil with your toothpaste, there’s a good chance you could benefit from some CBD before your dental appointment. Did you know that about 36 percent of people fear going to the dentist? That makes dentophobia one of the world’s more common panic disorders. 

Thankfully, there are plenty of studies that suggest CBD has natural anti-stress properties. If you take one dropperful of Tribe CBD oil at least 30 minutes before a dental appointment, we bet it could tame your dreaded dentophobia. 

To find out more about our high-quality hemp CBD oil, please check out this link. 

The news and editorial staff of the Bay Area News Group had no role in this post’s preparation.

DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism with Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of Fragile X syndrome and methods of treating one or more behavioral symptoms of autism spectrum disorder by transdermally administering a therapeutically effective amount of cannabidiol (CBD).

This new patent, which expires in 2038, is part of an expanding international intellectual property portfolio covering the Company’s transdermal cannabidiol product candidate, Zygel CBD gel. There are currently five corresponding U.S. patents related to methods of treating Fragile X syndrome or autism spectrum disorder.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, incentive and other tax credit eligibility, collectability and timing, and availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company’s product candidates may not be replicated or continue to occur in additional trials and may not otherwise support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration and foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company’s reliance on third parties to assist in conducting pre-clinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates the Company’s ability to commercialize its product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates; the Company’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the timing and outcome of current and future legal proceedings; and the extent to which health epidemics and other outbreaks of communicable diseases, including COVID-19, could disrupt our operations or adversely affect our business and financial conditions. This list is not exhaustive and these and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Contact

Peter Vozzo
ICR Westwicke
Office: 443.213.0505
Cell: 443.377.4767
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>

The Bloody Mary may be the “diva of drinks,” but that doesn’t mean the Bloody Caesar is just a cheap knock-off. In fact, if you’re a Canadian, chances are you’re more familiar with this later cocktail creation. Despite its Italian-inspired origin, the Bloody Caesar still holds its title as the official cocktail of the Great White North.

If you’re already a fan of the Bloody Mary, then you’re going to love our CBD rendition of Canada’s favorite drink. An extra dose of our high-quality CBD oil will keep you calm as you sip this spicy mix. 

CBD Bloody Caesar Recipe

Clamato juice is the main ingredient that distinguishes a Bloody Caesar from a Bloody Mary. For those who’ve never tried this Mott’s-owned product, it’s basically a combination of tomato juice, clam broth, and spices. Think V8 with some extra “fishiness.” 

While an “authentic” Bloody Caesar should include a few ounces of Clamato, that doesn’t mean you have to run out to the store and order this juice. In fact, it’s not all that difficult to make a DIY Clamato. Not only is it cheaper to make Clamato at home, you could easily adjust your drink to your tastes. 

To make Clamato at home, all you need are a few cups of tomato juice, ½ cup of clam juice, and whatever spices or citrus juices you prefer. Common secondary ingredients include Worcestershire sauce, black pepper, celery salt, and lemon juice. As long as you keep this mix in a sealed jar, it should last at least five days in your refrigerator. 

Ingredients

• A plate of celery salt
• 1 ½ ounces vodka 
• 4 ounces Clamato juice 
• 2 dashes Worcestershire sauce 
• 2 dashes Tabasco sauce 
• 1 – 2 dashes horseradish
• 1 dropperful Tribe CBD oil (citrus) 
• Lime wedge 
• Celery stalk

Directions

• Run a lime wedge around your highball glass
• Dip the glass in a plate of celery salt
• Pour everything but the lime wedge and celery stalk into a cocktail shaker
• Add ice and shake for a few seconds
• Strain into your highball glass
• Top with a lime wedge and celery stalk

Like the Bloody Mary, you could go crazy with garnishes on the Bloody Caesar cocktail. While a celery stalk is a crunchy classic, other common toppings include lemon wedges, olives, bacon, lime wheels, and a cucumber spear. 

Speaking of cucumbers, did you know Tribe CBD recently published a blog on how to make CBD-infused cucumber juice? If you’d like to learn how to make this hydrating beverage, be sure to click here. 

Get Your Blood Pumping With Tribe’s CBD Watermelon CBD Gummies

No question: a Bloody Caesar can wake you up, especially if you add a little extra hot sauce. However, we doubt you’ll be drinking this boozy beverage before your next workout. No, if you want to get pumped for a gym day, it’s better to turn to Tribe CBD’s Watermelon Gummies. Made with hemp-derived CBD, all-natural ingredients, no added sugar, these gummies are the perfect start to your workout routine. 

Please click here to find out more about Tribe’s best-selling CBD Gummies. 

It’s evident that CBD has grown in popularity worldwide.  The increased awareness is not unconnected with the growing research interest and the product’s potential health benefits. Those trying to buy this product for the first time might be overwhelmed by its sheer quantity.  The market comprises several CBD products; someone who does not know anything about CBD products might end up making the wrong choice. 

To avoid confusion, you should look into several factors before purchasing a CBD product.  For instance, you need to consider the potency of the product, the types of CBD oils for sale, the manufacturer, etc.

You must also be aware of the effect of CBD and how it interacts with other medications.  This knowledge will help you guide against the adverse reaction with other drugs. You should not hesitate to talk with the health care provider on CBD’s effect and its reaction with other medications.  

What is CBD?

Of course, you need to know what CBD is before attempting to buy a CBD product.  It’s a cannabinoid derived from the cannabis plant.  And it is next to the tetrahydrocannabinol (THC) hierarchy of abundance.  CBD acts differently on the body’s endocannabinoid system, leading to several effects, including sedative, anticonvulsive, anti-anxiety, and anti-inflammatory. 

Types of CBD

There is a vast range of cannabinoids extracts available on the market. To avoid confusion, you should acquaint yourself with the standard CBD-related terms. Bear in mind that some producers use these terms interchangeably. 

●       Broad-spectrum CBD

This type of CBD does not contain THC.  It usually comes with various other compounds, along with CBD, found in the plant.  Some of these compounds include terpene, CBN, or CBC. 

●       Full-Spectrum CBD

Unlike broad-spectrum CBD, this type usually contains about 0.3 percent THC, as approved by the federal law.  It is worth mentioning that this quantity is not high enough to cause a “high” effect that comes with the use of cannabis. 

The compounds in full-spectrum CBD are the same as that of Broad-spectrum products.  Note that this product may have an enhanced effect due to THC and other compounds’ presence. 

●       CBD Isolate

CBD isolate is different from the other types because it has one constituent, Cannabinoid, from the cannabis plant. This type of CBD does not contain THC or any other compound present in the plant. The advantage of CBD isolate is that it enables users to weigh the effect of cannabinoids alone with any influence from other compounds or substances.

What is COA?

One of the factors to consider before you buy a CBD product is the Certificate of Analysis.  This certificate confirms if the product contains the exact CBD content as advertised or claimed by the manufacturer. A COA should not come from the manufacturer; a third party must issue it. 

You can find a COA on the website of a CBD company; this allows prospective buyers to check out the contents of the product before making their buying decisions.  Furthermore, you must also check the source of the certificate; it must come from a trustworthy laboratory.

Potency Guide

The potency guide of a CBD product is an important feature that should not be overlooked. Note that it varies from one user to another, and it depends majorly on individual needs.

CBD doses come in milligrams.  However, it is worth noting that there is not enough research on the right dosage for various conditions.  Thus, start with lower doses and gradually increase it to find the dosage that works for you.  Once you have found your sweet spot, you should stick to it. 

CBD dosage of a user depends on several factors, including tolerance level, intake method, and users’ metabolism. 

Helpful Tips for Buying CBD products

No doubt, you have understood some essential factors that you should consider when purchasing a CBD product. That is not all; there are some helpful tips you need to consider before you place an order.  Whether you are a newbie or experienced CBD buyer, the following tips will surely guide you towards buying the best CBD products.

●       Go for Organic CBD Product

There are several similar-looking CBD products on the market. Therefore, you should use some essential criteria to narrow down your selections. 

So, one of these strategies is to buy organic CBD oils. Organic CBD oils are extracted from organic hemp plants.  It is a unique plant that has been used for hundreds of years to remove impurities from the soil.  A CBD product from this source does not contain any harmful pesticides and comes from one of the purest raw materials.  

●       Select a Full-Spectrum CBD oil

The advantage of a full-spectrum CBD product is that it contains several active compounds that will boost the product’s effectiveness.  These compounds work together to create the entourage effect, which can be explained as a natural synergy among all hemp constituents.  CBD is the main ingredient, but its effect on the body will not be significant without the support of terpenes and other cannabinoids compounds. 

●       Select a Product with Maximum Bioavailability

Bioavailability is another crucial factor to consider when buying a CBD product. Essentially, it means the amount of CBD that can be absorbed by the body. 

CBD oil drops are easily absorbed in the body compared to other CBD products. They can be absorbed directly through the capillaries located under the tongue. On the other hand, the CBD capsule will have to get to the stomach and pass through different digestive stages before it finally gets to the bloodstream.

●       Demand for Third-Party Lab Test Results

One of the ways to know the contents of the CBD product is to check the lab result.  However, some lab results do not give the actual content of a CBD product.  To avoid being misled by an inaccurate result, ask for a third-party laboratory test result; it is the only way to ensure that the content of the CBD oil for sale is not different from what is on its label. 

●       Check Customers Reviews

The review of past users of the product speaks volumes. So, you must take time to go through the customers’ comments on the CBD product you are about to buy. You can learn a lot from peer review sites.  You can also learn more about this product from Google or Facebook. 

What you really need to know

Our body systems do not react to CBD products the same way. Therefore, you should find out what works for you and stick to it. With the tips given above, you are sure to have a great chance of buying a high-quality CBD product that will suit your taste.

The usage of CBD is growing nowadays. Lots of people are using CBD just to get relief from all kinds of anxiety due to an increase in depression. In modern times, even animals are taking the CBD isolate, capsules or oil. The CBD is mainly given by the owners to their pets just to provide them some relief from the anxiety. There are lots of dogs and cats who are taking the non-toxic CBD.

CBD has really become one of the hottest consumer products. In a survey, it has shown that customer purchases for Cannabis products for themselves or for their pets have increased since the Cannabis chemical company received its license. CBD is being added to lots of things just for pets. This includes tea, body lotion and even meatballs.

It has also been noted that Americans have spent $33 billion on pet foods that are made of CBD. In the year 2018, the purchasing of CBD pet products has been increased to $32 million but in 2017, it was just $2 million.

Why CBD should be used by pets?

The owners are just giving CBD to reduce the seizures in their pets. In a study, it has been shown that the usage of the CBD has reduced the seizure in dogs who are suffering from epilepsy and provide relief to dogs who have osteoarthritis. The Department of the Food and Drug Administration has not approved any type of product for human or pets use. It is against giving CBD to pets. The FDA said that there may be some harmful effects if you are giving CBD to your dogs or cats.

What are the diseases that can be cured by using CBD?

Anxiety

Seizure

Epilepsy

Osteoarthritis